منابع مشابه
Developing an instrument to measure effective factors on clinical learning
Introduction: Although nursing students spend a large partof their learning period in the clinical environment, clinicallearning has not been perceived by its nature yet. To develop aninstrument to measure effective factors on clinical learning innursing students.Methods: This is a mixed methods study performed in 2 steps.First, the researchers defined “clinical learning” in nursingstudents thr...
متن کاملWomen in clinical trials: an FDA perspective.
Drug Administration (FDA) has been interested in the individualization of therapy, that is, determining whether and how treatment should be modified for various demographic groups within the population. After several years of discussion, a guideline was published on the study of drugs in the elderly (1), and later a similar guideline on the study and evaluation of gender differences in the clin...
متن کاملHandwriting Difficulties: Introducing an Instrument
Objectives: The main purpose of this study is to produce an instrument for handwriting evaluation and to execute it on mentally retarded (MR) students. Methods: This was a descriptive, cross-sectional, and relationship study. 126 MR students (53 girls and 73 boys) ranging from 9 to 19 years old (13.23±2.17) from two exceptional children schools in shahr-e-rey participated in this study. A ha...
متن کاملdeveloping an instrument to measure effective factors on clinical learning
introduction: although nursing students spend a large part of their learning period in the clinical environment, clinical learning has not been perceived by its nature yet. to develop an instrument to measure effective factors on clinical learning in nursing students. methods: this is a mixed methods study performed in 2 steps. first, the researchers defined “clinical learning” in nursing stude...
متن کاملBiologics clinical trials, research, and FDA actions.
Hopes raised, hopes dashed — the last half of 2012 has seen plenty of both. Enthusiasm over a bumper crop of U.S. Food and Drug Administration approvals has been tempered by a long list of phase 3 trial disappointments. Oncology agents led the way, starting with two drugs being studied for the treatment of non-small cell lung cancer. The addition of Eli Lilly’s pemetrexed (Alimta) to a regimen ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Chemistry
سال: 1975
ISSN: 0009-9147,1530-8561
DOI: 10.1093/clinchem/21.6.782